---
title: "Mineralys to present lorundrostat Explore-OSA hypertension trial data at AHA Hypertension Scientific Sessions 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300722541.md"
description: "Mineralys Therapeutics announced that new clinical and preclinical data on lorundrostat will be presented at the AHA Hypertension Scientific Sessions 2026. Key highlights include an oral presentation on the Explore-OSA trial for obstructive sleep apnea with hypertension, analyses from the Launch-HTN study in resistant hypertension, and preclinical findings showing reduced cardiorenal injury. The event takes place October 7-11."
datetime: "2026-10-01T20:06:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300722541.md)
  - [en](https://longbridge.com/en/news/300722541.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300722541.md)
generator: "portal-rs"
---

# Mineralys to present lorundrostat Explore-OSA hypertension trial data at AHA Hypertension Scientific Sessions 2026

-   Mineralys Therapeutics announced new clinical and preclinical lorundrostat data will be presented at AHA Hypertension Scientific Sessions 2026 on Oct. 7-11. \* A featured oral presentation will cover the Explore-OSA randomized crossover trial in obstructive sleep apnea with hypertension, focusing on efficacy and safety. \* Additional presentations will highlight analyses from the Launch-HTN study in uncontrolled and resistant hypertension, including responder outcomes. \* Preclinical findings slated for posters indicate lorundrostat reduced cardiorenal injury in a rat model, separate from blood pressure lowering. \* Market-use research will review real-world spironolactone treatment patterns and adherence to mineralocorticoid receptor antagonists in resistant hypertension. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610011605PRIMZONEFULLFEED9838220) on October 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [MLYS.US](https://longbridge.com/en/quote/MLYS.US.md)

## Related News & Research

- [Will AHA Trial Data Change Mineralys Therapeutics (MLYS) Narrative](https://longbridge.com/en/news/300872529.md)
- [Mineralys Therapeutics CEO Jon Congleton disposes of $1,909,665 common shares](https://longbridge.com/en/news/300830702.md)
- [Mineralys says Transform-HTN extension data on lorundrostat set for late-breaking AHA 2026 presentation](https://longbridge.com/en/news/299938459.md)
- [Mineralys director Brian Taylor Slingsby disposes of 104,320 common shares for $3 million](https://longbridge.com/en/news/300091813.md)
- [AI's $31.6T Buildout Faces a $6T Revenue Test](https://longbridge.com/en/news/300877631.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**